Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma A systematic review and meta-analysis /
Complete surgical removal is currently considered to be the best treatment option for pulmonary sarcomatoid carcinoma (PSC) especially in early stage operable disease; however, the reported recurrence-free survival is low. Benefits of adjuvant chemotherapy in PSC patients are still controversial, an...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | SURGICAL ONCOLOGY-OXFORD
44 |
| Tárgyszavak: | |
| doi: | 10.1016/j.suronc.2022.101824 |
| mtmt: | 33049438 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26679 |
| LEADER | 02444nab a2200265 i 4500 | ||
|---|---|---|---|
| 001 | publ26679 | ||
| 005 | 20230306091644.0 | ||
| 008 | 230306s2022 hu o 0|| Angol d | ||
| 022 | |a 0960-7404 | ||
| 024 | 7 | |a 10.1016/j.suronc.2022.101824 |2 doi | |
| 024 | 7 | |a 33049438 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 2 | |a Zombori-Tóth Noémi | |
| 245 | 1 | 0 | |a Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma |h [elektronikus dokumentum] : |b A systematic review and meta-analysis / |c Zombori-Tóth Noémi |
| 260 | |c 2022 | ||
| 300 | |a 6 | ||
| 490 | 0 | |a SURGICAL ONCOLOGY-OXFORD |v 44 | |
| 520 | 3 | |a Complete surgical removal is currently considered to be the best treatment option for pulmonary sarcomatoid carcinoma (PSC) especially in early stage operable disease; however, the reported recurrence-free survival is low. Benefits of adjuvant chemotherapy in PSC patients are still controversial, and there is no obvious agreement on the optimal treatment modalities of this disease. Therefore, we aimed to investigate the prognosis in terms of overall survival (OS) in patients with PSC who received adjuvant chemotherapy.The review protocol was registered in PROSPERO (CRD42022306084). Patients with PSC who underwent surgical therapy with or without adjuvant chemotherapy were included into the meta-analysis. Hazard ratios (HR) with 95% confidence intervals (CIs) for OS were pooled and ROBINS-I tool was used to assess risk of bias of the included studies.We identified four retrospective cohort studies with 6768 records from MEDLINE, Embase, and CENTRAL databases up to 9th September 2021, and altogether 1835 patients were included to the analysis. The present meta-analysis shows that patients receiving adjuvant chemotherapy had a significantly longer OS than patients who underwent surgical treatment alone (HR = 0.5657, 95%CI: 0.4391-0.7290, p < 0.0001).Despite the limited information on the chemotherapy regimens in the included studies, patients with PSC may benefit from adjuvant chemotherapy. More publications are required to evaluate and compare efficient adjuvant chemotherapy protocols in PSC cases. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Kiss Szabolcs |e aut |
| 700 | 0 | 1 | |a Ostarijas Eduard |e aut |
| 700 | 0 | 1 | |a Alizadeh Hussain |e aut |
| 700 | 0 | 1 | |a Zombori Tamás |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/26679/1/PSC_kozlemeny.pdf |z Dokumentum-elérés |